RAC1 and acute myeloid leukemia: A previous study suggested that knocking down DOCK2 could sensitize FLT3-ITD leukemic cells to cytarabine treatment through the inhibition of Rac1 pathway 24, whereas in this study, we observed a favorable prognostic impact of high DOCK2 expression in AML patients.